NOAA Signs CRADA with Biosortia Phramaceuticals
Agreements seeks to isolate and commercialize new compounds for human health benefits
The U.S. Department of Commerce, National Oceanic and Atmospheric Administration (NOAA), National Ocean Service, National Centers for Coastal Ocean Service, Center for Human Health Risk at Hollings Marine Laboratory (CHHR/HML) and Biosortia Pharmaceuticals dba Alagaeventure Systems (AVS) entered into a CRADA.
The purpose of the agreement is to provide a 5-year framework for research and development regarding the analysis and purification of novel bioactive compounds. If successful, this research will result in the commercial development of new and unique chemical compounds from the sea which have benefits to human health, either through disease prevention or new treatments for disease.
NOAA's Center For Human Health Risk at the HML
NCCOS’s Center for Human Health Risk (CHHR) conducts research to understand and forecast relationships between coastal ocean ecosystems and human health and make information and tools available to managers and public health officials.
Click to Learn more about NCCOS and CHHR. Read more about this agreement and the technology behind this research activity here.